In addition to its current indication as second‐line treatment in patients with refractory hypocalcaemia, our results support the use of PTH replacement therapy in patients in whom hyperphosphatemia and increased urinary calcium excretion are a clinical concern. Here, PTH is linked to Hypocalcemia.